Eli Lilly’s (LLY) latest AI move reads less like a side project and more like a statement: the drugmaker is quietly trying to turn biology into software—and it just hired Profluent as one of its lead engineers.
Lilly Bets Big On AI-Authored Biology
Eli Lilly has signed a gene-editing and protein-design collaboration with AI startup Profluent, a deal that could be worth up to $2.25 billion if all development and commercial milestones are met. Under the agreement, Lilly secures exclusive rights to any medicines that emerge from Profluent’s platform, while Profluent receives an undisclosed upfront payment, committed R&D funding, and the potential for tiered royalties on net sales.
The companies are aiming at one of genetic medicine’s more stubborn challenges: building next-generation DNA editors, including recombinases, that can precisely insert long stretches of DNA into chosen locations in the genome—essentially moving from snipping genes to rewriting paragraphs. Specific disease targets and program counts have not yet been disclosed, underscoring how early the work is and how much of the value here lies in platform potential rather than near‑term product launches.
Inside Profluent’s “Programmable Biology” Playbook
Profluent, based in Emeryville, California, describes itself as a frontier AI company building large-scale foundation models for protein design—treating proteins less like mysteries of nature and more like outputs of a very large, very opinionated autocomplete engine. The startup has assembled what it calls the largest protein data resource in the world, an atlas of over 115 billion unique proteins, and has demonstrated that large language models can generate novel, functional proteins de novo rather than merely tweak existing ones.
Backed by investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, and Air Street Capital, Profluent has raised roughly $150 million to scale its AI platform across therapeutics, diagnostics, agriculture, and biomanufacturing. Its mission is to make biology “programmable,” shifting drug discovery from painstaking trial‑and‑error toward engineered solutions where AI proposes bespoke proteins designed to solve specific clinical problems. In Lilly’s case, that means AI‑designed recombinases and other genetic tools that could one day make inserting full, healthy genes into diseased tissues feel less like moonshot science and more like precise infrastructure work.
A Deal Structure Built For Optionality
The financial architecture of the Lilly–Profluent pact says as much as the press release. Profluent stands to receive up to $2.25 billion through a ladder of development and commercial milestones, plus royalties on any eventual product sales, but the upfront payment remains undisclosed—classic “biobucks” territory that lets Lilly keep near‑term risk modest while preserving meaningful upside if the science hits.
For Lilly, the exclusive rights to drugs generated from Profluent’s platform create a kind of call option on the next generation of gene editing, giving the company first claim on AI‑designed therapies that could complement its existing franchises in obesity, diabetes, and other complex diseases. For Profluent, the structure effectively funds platform expansion while using Lilly’s global development and commercialization engine as the distribution layer for its AI‑authored biology. In Wall Street terms, Lilly keeps the balance sheet light today while buying long‑dated exposure to what some investors are already calling the “holy grail” of genetic medicine.
Part Of A Broader AI Supercycle At Lilly
This is not Lilly’s first AI pas de deux, and it likely won’t be its last. The company recently expanded its collaboration with Insilico Medicine, an
, in a deal that includes an initial payment of about $115 million and milestones that could take the total value to roughly $2.75 billion, with Lilly gaining exclusive rights to certain AI‑discovered drug candidates.
On the infrastructure side, Lilly has also teamed up with NVIDIA to build what the partners have described as one of pharma’s most powerful AI supercomputers, supported by up to $1 billion in joint investment and anchored by a co‑innovation lab in the San Francisco Bay Area. The idea is not just to “use AI” but to own industrial‑scale AI capabilities—from model training on millions of experiments to a TuneLab‑style platform where external biotechs can plug into Lilly’s models via federated learning. Put differently, Lilly is trying to be the place where biology meets compute at scale, and Profluent’s deal sits squarely inside that ambition.
What It Signals For Investors And Drug Development
For investors watching Eli Lilly, the Profluent partnership adds another layer to a thesis that’s already centered on durable growth in metabolic disease and an aggressive build‑out in next‑generation modalities. The company is effectively layering AI-driven discovery and gene editing tools on top of its commercial engine, betting that faster design cycles and more precise genetic interventions will help sustain its pipeline well into the 2030s.
The milestone-heavy structure, the absence of disclosed disease targets, and the emphasis on platform capabilities should also serve as a reminder: this is foundational R&D, not a near‑term earnings lever. Still, in an industry where traditional drug development can take a decade and cost more than $1 billion per asset, the prospect of AI‑designed editors and proteins that compress timelines and open up previously “undruggable” biology is the kind of asymmetric upside Wall Street tends not to ignore for long. If Lilly and Profluent are right, the next blockbuster might not just be discovered in the lab—it may be co‑written by an algorithm that treats DNA like code and proteins like a new asset class.
The Sources
- Bloomberg – “Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion”
https://www.bloomberg.com/news/articles/2026-04-28/lilly-profluent-ink-deal-on-ai-drugs-worth-up-to-2-25-billionbloomberg - Business Wire – “Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicines”
https://www.businesswire.com/news/home/20260428698315/en/Profluent-Announces-Strategic-Partnership-with-Lilly-to-Develop-AI-Desibusinesswire - Reuters – “Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion”
https://www.reuters.com/business/healthcare-pharmaceuticals/profluent-lilly-partner-genetic-medicine-deal-worth-up-225-billionreuters - BioSpace – “Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’”
https://www.biospace.com/deals/lilly-ai-biotech-profluent-ink-2-25b-pact-in-search-of-genetic-medicine-holy-grailbiospace - Yahoo Finance / Healthcare – “Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion”
https://finance.yahoo.com/sectors/healthcare/articles/profluent-lilly-partner-genetic-medicine-111848875.htmlfinance.yahoo - LinkedIn News – “Eli Lilly commits up to $2.25B to AI drug development”
https://www.linkedin.com/news/story/eli-lilly-commits-up-to-225b-to-ai-drug-development-8738506/linkedin - STAT News – “Eli Lilly enlists AI startup for next-generation gene editors”
https://www.statnews.com/2026/04/28/eli-lilly-crispr-gene-editing-deal-profluent-ai/statnews - Fierce Biotech – “Lilly pens $2.2B gene editing pact with Bezos-backed Profluent”
https://www.fiercebiotech.com/biotech/lilly-pens-22b-pact-bezos-backed-profluent-work-recombinase-based-gene-editingfiercebiotech - Simply Wall St – “Eli Lilly Expands Into AI DNA Editing With Profluent Enzyme Deal”
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/eli-lilly-expands-into-ai-dna-editing-with-profluent-enzyme-dealsimplywall - Pharmaphorum – “AI start-up Profluent nabs Lilly as first big pharma partner”
https://pharmaphorum.com/news/ai-start-profluent-nabs-lilly-first-big-pharma-partnerpharmaphorum - American Pharmaceutical Review – “Profluent and Lilly Sign Multi-Program AI Partnership to Develop Recombinase-Based Gene Editing Medicines”
https://www.americanpharmaceuticalreview.com/1315-News/625398-Profluent-and-Lilly-Sign-Multi-Program-AI-Partnership-to-Develop-Recombinase-Based-Gene-Editing-Medicinesamericanpharmaceuticalreview - Indianapolis Business Journal – “Lilly signs $2.25B deal with California-based AI firm to develop genetic medicine”
https://www.ibj.com/articles/lilly-signs-2-25b-deal-with-california-based-ai-firm-to-develop-genetic-medicineibj
